Physician profile
George Corbett
NPI 1760478440
$2,884.75
in general payments reported to CMS, 2019-2025
14 companies · $1,880 in 2025
The $1,880 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $149 · 2021: $248 · 2022: $107 · 2023: $45.89 · 2024: $202 · 2025: $1,880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105 · Travel and Lodging: $946 · Education: $77.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.93 |
| Travel and Lodging | $945.66 |
| Education | $77.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $1,494.55 | 2025 | Oxford |
| Smith+Nephew, INC. | $641.04 | 2019-2025 | Evos, Intellio Link Werewolf, Kvac |
| Depuy Synthes Sales INC. | $186.35 | 2019-2025 | Monovisc, Orthovisc, Truespan Orthocord |
| Djo, LLC | $97.50 | 2025 | Cmf |
| Ferring Pharmaceuticals INC. | $95.77 | 2020-2025 | Euflexxa |
| Pacira Therapeutics, INC. | $84.79 | 2019-2021 | |
| Orthalign INC | $74.66 | 2025 | Orthalign Plus |
| Dynasplint Systems INC. | $69.41 | 2021 | |
| Horizon Therapeutics Plc | $42.57 | 2019-2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $32.96 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $24.60 | 2025 | |
| Ethicon US, LLC | $14.87 | 2020 | |
| Vericel Corporation | $13.27 | 2021 | |
| Acumed LLC | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Corbett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.